Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rudy Bohinc

Internal Medicine Sidney, OH Medical Doctor

NPI 1558310995 CMS profile 919912

661 N Vandemark Rd, Sidney, OH 45365

Open in the dashboard

General payments

$8,226

577 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rudy Bohinc of Sidney, OH is reported in the CMS Open Payments database as having received $8,226 across 577 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $802 47
2024 General $1,518 97
2023 General $1,572 98
2022 General $1,350 98
2021 General $1,373 114
2020 General $717 53
2019 General $894 70

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rudy Bohinc
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Rudy Bohinc were reported at $802. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Rudy Bohinc Internal Medicine median Middle half National median
2019 $894 $159 $48–$570 $163
2020 $717 $119 $33–$402 $114
2021 $1,373 $135 $37–$521 $132
2022 $1,350 $141 $42–$496 $149
2023 $1,572 $149 $45–$519 $160
2024 $1,518 $154 $47–$537 $164
2025 $802 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $983 72 payments
  2. AstraZeneca Pharmaceuticals LP $890 49 payments
  3. Novo Nordisk Inc $815 71 payments
  4. Lilly USA, LLC $753 52 payments
  5. Pfizer Inc. $597 51 payments
  6. GlaxoSmithKline, LLC. $445 34 payments
  7. Amgen Inc. $435 30 payments
  8. Janssen Pharmaceuticals, Inc $348 24 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $285 21 payments
  10. Abbott Laboratories $253 15 payments
  11. Other $2,426 158 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,220 575 payments
  2. Education $7 2 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $639 34 payments
  2. Ozempic $495 44 payments
  3. MOUNJARO $440 28 payments
  4. TRELEGY ELLIPTA $420 32 payments
  5. NURTEC ODT $371 30 payments
  6. RYBELSUS $369 32 payments
  7. XARELTO $328 23 payments
  8. VRAYLAR $317 23 payments
  9. UBRELVY $248 19 payments
  10. BREZTRI $246 9 payments
  11. Other $6,970 484 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 172 drugs

Part D claims

11,937

Median for Internal Medicine: 777

Drug cost

$619,184

Median for Internal Medicine: $73,373

Branded share of claims

23.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 98 $84,128
Jardiance Empagliflozin Brand 95 $78,306
Ozempic Semaglutide Brand 48 $51,557
Farxiga Dapagliflozin Propanediol Brand 73 $44,152
Mounjaro Tirzepatide Brand 29 $30,312
Trulicity Dulaglutide Brand 21 $23,723
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 34 $21,736
Janumet Sitagliptin Phos/Metformin Hcl Brand 13 $20,220
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 21 $17,760
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 21 $17,070

The 10 drugs with the highest cost, of 172 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$59,008

Of which drugs: $3,740

Medicare patients

313

Average age 75

Services billed

1,292

156 women, 157 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 40%
Diabetes 33%
Ischemic heart disease 33%
Atrial fibrillation 25%
Depression 20%
Chronic kidney disease 19%
Heart failure 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 35 35 $2,782
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 12 53 $36

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 35 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $140
$140 29 —
VRAYLAR
  • AbbVie, Inc. $87
$87 — —
NURTEC ODT
  • PFIZER INC. $75
$75 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $71
$71 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $66
$66 73 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 35 with Patron

Records

577 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record